Milbemax 16 mg/40 mg Film-coated Tablets for Cats

The possibility that other animals in the same household can be a source of re-infection
should be considered, and these should be treated as necessary with an appropriate
veterinary medicinal product.
It is recommended to treat all the animals living in the same household concomitantly.
When infection with the cestode D. caninum has been confirmed, concomitant
treatment against intermediate hosts, such as fleas and lice, should be discussed with a
veterinarian to prevent re-infection.
Unnecessary use of antiparasitics or use deviating from the instructions given in the
SPC may increase the resistance selection pressure and lead to reduced efficacy. The
decision to use the veterinary medicinal product should be based on confirmation of the
parasitic species and burden, or of the risk of infection based on its epidemiological
features, for each individual animal.
In the absence of risk of co-infection with nematodes or cestodes, a narrow spectrum
veterinary medicinal product should be used when available.
The use of this veterinary medicinal product should take into account local information
about susceptibility of the target parasites, where available.

Special precautions for safe use in the target species:
Ensure cats and kittens weighing between 0.5 kg and ≤2 kg receive the appropriate
tablet strength (4 mg MBO/10 mg praziquantel) and the appropriate dose. See also
section 3.9.
No studies have been performed with severely debilitated cats or individuals with
seriously compromised kidney or liver function. The veterinary medicinal product is not
recommended for such animals or only according to a benefit/risk assessment by the
responsible veterinarian.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals:
Wash hands after use.
In case of accidental ingestion of the tablets, particularly by a child, seek medical advice
immediately and show the package leaflet or the label to the physician.
Special precautions for the protection of the environment:
See section 5.5.
Other precautions:
Echinococcosis represents a hazard for humans. As Echinococcosis is a notifiable
disease to the World Organisation for Animal Health (WOAH), specific guidelines on the
treatment and follow up and on the safeguard of persons need to be obtained from the
relevant competent authority (e.g. experts or institutes of parasitology).